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ABSTRACT 
The objective of the present research was to develop folic acid conjugated polymeric nanoparticles (FCsPNP) and to investigate its therapeutic 
effectiveness in xenograft Colon tumor models after oral delivery. Chitosan coated PLGA nanoparticles (CsPNP) were prepared by 
polyelectrolyte complexation method and it was further conjugated with Folic acid. Optimized formulation was investigated for particle size, 
zeta potential, polydispersity index (PdI), % entrapment drug loading and in vitro release. The morphology was observed by SEM and TEM 
images. Tumor regression studies were conducted on Balb/c mice implanted with Colo-26 cells. FCsPNP were successfully prepared and 
optimized. In vitro parameters viz. Particle size, Zeta potential, PdI were found to be optimum. The in vitro % release is directly correlated with 
the nature of polymers and folate conjugation. In vivo tumor regression studies found the formulations to be less toxic than Irinotecan 
hydrochloride (IHCl). CsPNP and FCsPNP were successfully prepared and evaluated for antitumor efficacy after oral delivery. FCsPNP were 
more effective in the colon tumor treatment and found to be less toxic than IHCl thus making it a potential drug delivery candidate for future 
anticancer therapy. 
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INTRODUCTION 
Colorectal cancer is third widely diagnosed cancer in the 
whole world1. Effective chemotherapy is still the need of 
hour as in spite of so many researches the side effects and 
toxicity of chemotherapeutic agents are still prevailing in the 
cancer patients. Multifunctional nanoparticles have reached 
many milestones in the field of anticancer research2,3. 
Polymeric nanoparticles have shown excellent therapeutic 
efficacy in colorectal cancer treatment3,4. Because of the 
numerous advantages of nanoparticles they are mainly used 
for controlled delivery of drugs and imaging agents and have 
attracted remarkable interests in recent years 5,6. Drugs are 
protected from being degraded during in vivo by these 
nanoparticles. They provide targeted and controlled drug 
release and are capable of accumulating in colon tumor by 
active and passive targeting mechanisms. However, after 
intravenous administration nanoparticles are often 
eliminated rapidly by macrophages present in the reticulum 
endothelial system (RES) which are located mainly in the 
liver and spleen and which leads to short circulation half-life 
after intravenous administration7,8. Oral chemotherapy is not 
only convenient but can also greatly improve the quality of 
life of the patients. This is especially important for the 
patients with advanced or metastatic cancer. Oral 
chemotherapy can eventually start a new concept of 
chemotherapy: ‘chemotherapy at home’9-11. In the present 
research polymeric nanoparticles are developed by 
polyelectrolyte complexation method using a cationic 
polymer (Chitosan) and an anionic polymer (PLGA). Chitosan 
is a biodegradable and versatile polymer which is soluble in 
acidic media and is used for colonic delivery. These are 
hydrophilic, natural and positively charged polymer which 
interacts with negatively charged polymers, polyanions and 
macromolecules. Polyelectrolyte complexation is a method 
for the formation of nanoparticles and it has a potential for 
oral controlled release12,13. These nanoparticles are better 
than other synthetic nanoparticles as they are more stable, 
have simple preparation methods, low toxicity and can be 
given by versatile routes of administration12-14. PLGA 
(Poly(lactide-co-glycolide) is biodegradable polymer widely 
used for the formation of polymeric nanoparticles as they 
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can provide a solution to adjuvant therapy and may provide 
a better efficacy and fewer side effects. It is a frequently-used 
drug delivery carrier for nanoparticulate systems15-17. 
Biodegradable polymer can be used as carriers for drug and 
for the preparation of biodegradable NPs. Other advantages 
of biodegradable NPs include lesser frequency of 
administration, less systemic side effects, sustained drug 
release and reduced dosage 7, 15, 18. PLGA is approved for 
human use by the USFDA as implantable devices, surgical 
sutures and drug delivery systems. Chitosan and PLGA are 
applied as Pgp (Para glyco protein) inhibitors and are also 
used as drug carriers 19,20. SN-38 (7-ethyl-10-
hydroxycamptothecin) is 1000 fold more cytotoxic than CPT-
11. It has anticancer activity against colon cancer, lung 
cancer, cervical cancer and pancreatic cancer. It is the active 
metabolite of Irinotecan (CPT-11), which is a topoisomerase 
I inhibitor and is available commercially as Camptosar® 21-23. 
It has poor aqueous solubility and poor oral bioavailability 
(8%) 24. It is formed in the liver and tumors from CPT-11 but 
its metabolic conversion rate is less than 10% of the original 
volume of CPT-1125. For increasing the hydrophilicity, 
bioavailability and for providing sustained action various 
approaches like, Liposomes, Polymeric micelles, 
Nanoparticles and Polymer drug conjugates were prepared 
but most of these formulations were given by intravenous 
administration although oral administration is chosen by 
89% patient3. Folic acid is widely used as a targeting ligand 
to deliver the polymeric nanoparticles (NPs) into cells 
primarily via receptor-mediated endocytosis 26,27. Folate-
receptor-targeted SN-38 NPs was produced earlier using 
PLGA NPs covalently bound to Poly (ethylene glycol)-folate, 
which demonstrated more cytotoxicity on HT-29 cells as 
compared to control NPs 28-30. These nanoparticles where 
given via the intravenous route and showed that the 
bioavailability of SN-38 was significantly increased 24,31. 
However, oral delivery of nanoparticles is more practical as 
compared with the intravenous route because of greater 
convenience, cheaper cost, better patient compliance and 
further simplicity for long-standing treatment of chronic 
diseases 9,32-34. The aim of present study is to determine the 
potential application of Folate conjugated chitosan coated 
PLGA NPs for improving the oral absorption of SN-38 and to 
show its therapeutic effectiveness against solid colon tumor. 
MATERIAL AND METHODS 
Material 
SN-38 was obtained from Avra Labs (Hyderabad, India). 
PLGA (50:50) (Resomer®) was obtained from Evonik 
Industries (Mumbai, India). All other solvents and chemicals 
are of analytical grade purchased from Hi Media Labs 
(Mumbai, India).  
Methods 
Preparation of Chitosan coated PLGA nanoparticles 
(CsPNP) 
CsPNP was prepared by polyelectrolyte complexation 
method as given by Prasad et al 22. Briefly, Pluronic F 68 was 
added to chitosan and magnetically stirred at room 
temperature 35. This dispersion is added to SN-38 dispersed 
in PLGA solution with a syringe and was stirred overnight. 
Then it was centrifuged, sonicated, sediment was washed 
and lyophilized. The nanoparticles thus formed was 
preserved at 2-4oC till further use. 
Preparation of folic acid (FA) conjugated CsPNP 
(FCsPNP) 
5mg of FA and 4 ml of NPs suspension (5mg/ml, distilled 
water used as solvent) were co-mixed in the presence of 10 
mg of (Ethyl-3-(3-dimethylaminopropyl) carbodiimide 
hydrochloride) EDC and 19 mg of (N-hydroxy Succinamide) 
NHS and stirred at room temperature under dark condition 
for 2 hr and a yellow FA-NPs suspension was obtained 36,37. 
Then it was centrifuged, sediment washed and lyophilized 
for 48 hrs. 
In Vitro Characterization  
Particle size, polydispersity index (PdI) and zeta 
potential   
The mean particle size and PDI were determined by particle 
size analyzer (SALD 2201, Shimadzu) and zeta potential was 
determined by Zetasizer (Nano ZS 90, Malvern Instruments).  
In vitro release in simulated gastrointestinal fluids 
The in vitro release studies were conducted by a dialysis 
membrane method with modification22. The membrane was 
soaked in double-distilled water for about 12 h, prior using 
the membrane. SN-38 containing CsPNP were put inside 100 
ml of Simulated gastric fluid (SGF), Phosphate buffer saline 
(PBS) (pH 7.4), Simulated intestinal Fluid (SIF) and in 
Simulated Colonic Fluid (SCF) for 48 hrs after enclosing in a 
dialysis bag (MWCO 8 kDa, Hi Media, Mumbai). The tests 
were conducted at 37°C± 1°C in a constant temperature 
shower mixer at 100 rpm. The amount of SN-38 released was 
measured by HPLC, C-18 reverse phase (Young lin 
instrument, # 899-6, Korea) at a wavelength of 265 nm21. 
The Cumulative % release in SGF, SIF, SCF and PBS is shown 
in Fig. 2.  
Electron microscopic images 
Transmission electron microscopy (TEM) and Scanning 
electron microscopy (SEM) images evaluate the size and 
shape of optimized batch of nanoparticles. TEM images were 
taken by FEI Philips Morgagni 268D (2, 80,000x). TEM 
images are shown in Fig. 3. The shape and surface 
morphology of blank CsPNP and drug loaded CsPNP were 
investigated using scanning electron microscopy (SEM).The 
samples photomicrographs were taken with a SEM (Jeol JSM-
1600, Tokyo, Japan). The SEM images of blank CsPNP and 
SN-38 loaded CsPNP and FCsPNP are given in Fig. 4. 
Entrapment efficiency and drug loading 
CsPNP and FCsPNP (0.25%w/v) was dispersed in 
dichloromethane. To the above solution acetonitrile (5ml) 
was added and centrifuged for 20 minutes. After dilutions 
the supernatant was analyzed for SN-38 at a wavelength of 
265 nm with HPLC21.  
Entrapment efficiency% =      Wt of SN 38 calculated     X 100 
   Wt of SN 38 added 
Drug loading efficiency =      Wt of SN 38 calculated               x 
100 
          Wt of nanoparticles 
In Vivo Characterization 
Tumor regression studies on male Balb/c mice 
All in vivo studies were performed in accord with the study 
protocol as approved by the Institutional Ethical Committee, 
SLT Institute of Pharmaceutical Sciences, 
994/a/GO/06/CPCSEA, Guru Ghasidas Vishwavidyalaya, 
Bilaspur, Chhattisgarh, India. The studies were conducted on 
male Balb/c mice 6-7 week old obtained from ACTREC, Tata 
Memorial Centre, Navi Mumbai, India. Four groups (n=6) 
were taken. The animals were housed 15 days before the 
experiment and fed the usual commercial diet and water ad 
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libitum. All mice were pre weighed before experiment. 
Tumor was induced in the mice by subcutaneously injecting 
Colon-26 cells (1x 107 cells) as per the protocol of Morton et 
al 38. Treatment started when the implanted tumour reaches 
nearly 100mm3 in volume as measured by Vernier callipers 
as per the following formula, 
Tumor volume =  A x (B)2 
                                                      2                               
Where A and B are length and width of the tumor, 
respectively. 1st group was control group to which Normal 
saline solution (0.9%w/v) was given. 2nd, 3rd and 4th group 
were given FCsPNP, CsPNP and Irinotecan hydrochloride in 
solution form respectively, for 30 days orally at a dose of 80 
mg/Kg. Tumor volume was measured every 3-5th day. Body 
weight, clinical signs and mortality were observed during 
these 30 days. Animals which showed toxicity by clinical 
signs and body weight loss of 25% or more were considered 
as moribund and euthanized immediately.  
Statistical Analysis 
 Statistical analysis was performed with Graph Pad prism 
7.01. The mean data from different formulations were 
compared by one way ANOVA. Differences were considered 
significant when P < 0.05.   
Results  
Optimization of CsPNP and FCsPNP and in vitro 
characterization 
The formulation having 1.43% (w/v) polymer concentration, 
0.21% (w/v) surfactant concentration, and 7.25min 
sonication time is chosen as optimized formulation and 
prepared accordingly22. Particle size, entrapment efficiency, 
poydispersity index (PdI), zeta potential (ZP) and drug 
loading of CsPNP and FCsPNP are given in Table 1. 
Ultrasonication resulted in smaller nanoparticles. The 
magnetic stirring speed was optimized at 1200 rpm for 5hrs. 
0.25 % (w/v) of cationic polymer (chitosan) was kept fixed. 
FCsPNP were prepared by a method as given by Yang et al 
with modifications40.  Folic acid was added in the suspension 
with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) 
hydrochloride in the ratio of 1:3 after optimization of EDC 
concentration. Conjugation efficiency was determined and 
found to be 73.3 ± 2.1 % which show that folic acid is 
conjugated accurately with CsPNP. The schematic diagram of 
Folic acid conjugation with the polymers is shown in Fig.1. 
Electron microscopy 
TEM helps in the evaluation of size and shape of the 
optimized batch of nanoparticles. TEM images of the CsPNPs 
showed spherical shape of nanoparticles, non aggregation 
with narrow size distribution and without clumping of 
nanoparticles. Blank CsPNP were found spherical with 
nanocapsular structure and SN-38 loaded CsPNP were found 
having structures of nanospheres with matrix inside. The 
nanoparticles were in the size range of 90-200 nm as 
observed in the electron microscopic images. It shows that 
drug loaded nanoparticles were having a coating of chitosan 
with a matrix of SN-38 and PLGA inside. The particles were 
clearly visible with spherical structures in nanometre range. 
Surface morphology of blank CsPNP and drug loaded CsPNP 
were visualized by SEM images. It depicted rough surface of 
CsPNP. Rough surface is due to chitosan in the outermost 
layer of nanoparticles. It depicted the formation of 
nanoparticles in the range of 200-400 nm and with a rough 
surface. TEM images of FCsPNP were taken at a 
magnification of 40,000X and it was in the range of 70-180 
nm. The images (Fig. 3) clearly showed bilayer structure, one 
of chitosan and other of folic acid. SEM images (Fig. 4) were 
taken at magnification of 20,000X and it depicted spherical 
FCsPNP with somewhat smoother surface as compared to 
CsPNP, which reveals that the rough surface due to chitosan 
was covered with smooth layer of Folic acid. 
 In vitro drug release 
Drug release studies in simulated gastrointestinal fluids are 
done to simulate the human body metabolic activity in 
gastrointestinal fluid and colonic fluid. The release study of 
SN-38 from CsPNP was conducted for 96 hrs in simulated 
gastrointestinal fluids. There was negligible release of SN-38 
in SGF. In SIF (pH 6.8) it released nearly 62.9% drug and in 
SCF the release was 72.5% in 24 hrs and 84.7% in 96 hours. 
In PBS (pH 7.4) CsPNP released nearly 31.1% drug in 72 hrs. 
However, pure SN-38 released only 7.4 % drug in 72 hrs. The 
drug release for FCsPNP was conducted in Phosphate buffer 
saline (pH 7.4) for 72 hrs by dialysis membrane method. It is 
represented graphically in Fig. 2. It was found to release 
20.1% in 24 hrs and 22.1% in 72 hrs. 
In vivo characterization 
Tumour regression studies 
The tumor regression studies were conducted on xenograft 
colon tumor models of Balb/c mice transplanted with Colon 
26 cells. The photographs of colon tumor cells transplanted 
mice on 1st day and last day is shown in Fig.6. The 
percentages of survival of different groups are shown in Fig. 
5(A) and data shown in Table 2. It showed that plain aqueous 
solution of Irinotecan hydrochloride was more toxic as 
compared to other treated and untreated groups and the 
survival rate reached 67% on 28th day. Models treated with 
FCsPNP showed 100 % survival. CsPNP significantly showed 
better survival rate (83 %) on 28th day as compared to the 
positive control group. Tumor volume data and graph is 
given in Table 3 and depicted in Fig. 5(B) respectively. There 
was maximal control of tumor growth in the group which 
was treated with FCsPNP (Tumor volume reached 2.53 cm3) 
as compared to control groups (positive and negative) and 
CsPNP group. The animal weights taken at different time 
points are shown graphically in Fig. 5(C) and the data is 
given in Table 4. A weight loss ≥ 4 gm is considered to be 
toxic. No animal showed a weight loss of ≥ 4 gm and but 
there are significant differences in the animal weights of 
CsPNP and FCsPNP when compared with the positive and 
negative control groups (P<0.05). There is increase in the 
weight of control group due to uncontrolled tumor growth. 
In the treated groups 4th group treated with IHCl had 
significantly more weight loss as compared to 2nd and 3rd 
group.  
Graph of T/C values from RTV data of different groups 
with respect to days 
Relative tumor volume (RTV) was calculated as follows,  
RTV= Tumor volume on day of measurement 
    Tumor Volume on day 1 
It shows that FCsPNP significantly have maximum control on 
tumor growth and minimum on treatment with IHCl solution 
(P<0.05). The data of T/C values is depicted graphically in 
Fig. 5 (D) and given in Table 5. Antitumor activity is seen 
when T/C values ≤ 0.4. The data shows that FCsPNP is 
showing antitumor activity during the study period. 
However, CsPNP and IHCl is successful in controlling the 
tumor growth up to some extent (T/C values is nearly equal 
to 0.9). 
Discussions 
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Polyelectrolyte complexation is a novel method for the 
formation of chitosan based nanoparticles 41.  This method is 
economic and involves negligible use of organic solvents. 
Chitosan is a biodegradable polymer and is mainly used for 
colonic delivery. These are hydrophilic, natural and 
positively charged polymer which interacts with negatively 
charged polymers, polyanions and macromolecules. These 
nanoparticles are better than other synthetic nanoparticles 
as they are more stable, have simple preparation methods, 
low toxicity and can be given by versatile routes of 
administration. Poly lactic co glycolic acid (PLGA) is 
biodegradable polymer widely used for the formation of 
polymeric nanoparticles as they can provide a solution to 
adjuvant therapy and may provide fewer side effects and 
better efficacy 42,43. Polymeric nanoparticles can incorporate 
both hydrophilic and lipophilic drug and improves the oral 
delivery of those drugs having poor chemical, enzymatic or 
metabolic stability and permeability and releases the drug at 
a specific site 44,17. Stability of nanoparticles is indicated by 
high zeta potential (positive or negative) as particles which 
have high charge are dispersed and less aggregated and thus 
have lesser PdI 45,46. Poly dispersity index symbolises the 
homogeneity of dispersions. For a homogeneous suspension 
it should be less than 147. Here it was found to be 
homogeneous in nature.  Positive zeta potential is due to the 
concentration of chitosan being more than PLGA. Targeting 
moieties or ligands are very often used to specifically target 
the receptors of tumor cells and deliver them within cells by 
receptor mediated endocytosis. Folic acid (FA) is widely 
preferred in the delivery of anticancer agents due to its non 
immunogenic nature, small size, low cost and high tumor 
tissue specificity 48. Colorectal tumor cells are devoid of folic 
acid so folic acid linked nanocarriers have comparatively 
high binding affinity to folate receptors expressed on tumor 
cells 40. EDC acts as a catalyst for the coupling reaction 
between the carboxyl group of folic acid and free amino 
group of chitosan. The results of drug loading and 
entrapment efficiency show that conjugation with folic acid 
does not interfere with drug loading and entrapment 
efficiency. Zeta potential of FCsPNP is less than that of 
CsPNP.  It is due to the anionic nature of folic acid which 
compensates the positive potential of chitosan and decreases 
the overall zeta potential. Particle size of FCsPNP increased 
due to the conjugation with folic acid. However, for oral 
administration the size range of 200-400 nm is required to 
protect the particles from Pgp (Para-glycoprotein) efflux 
pump20. As these particles are in the range and are hence 
prevented from PgP efflux pump. The pattern of in vitro drug 
release by CsPNP shows sustained release action and there is 
very less release of SN-38 from FCsPNP in PBS (pH 7.4) due 
to poor solubility of lactone form of SN-38 in PBS. Guo and 
his team20 also found that the cumulative release 
percentages of SN-38 from chitosan nanoparticles in 24 hrs 
is 27.03% and it had very slow and sustained release in PBS 
at pH 7.4 during 7 days study. It also shows that CsPNP has 
more potential for drug release than pure SN-38 in PBS, but 
lesser in simulated colonic fluid. This pattern was sustained 
release and favoured the aim to target the drug for colon 
cancer by oral route. Antitumor efficacy data revealed that 
no animal showed a weight loss of ≥ 4 gm and there is not 
any significant change in the animal weight as compared to 
the initial weight when compared within the groups. When 
compared in between the groups there was significant 
difference in the weights of animals of the treated group and 
positive and negative control groups. It showed that the 
formulations are not showing any side or toxic effects to the 
animals. However, IHCl was found to be more toxic than 
FCsPNP and CsPNP according to the changes in weight of the 
animals. Relative tumor volume data shows that the control 
on tumor growth is predominantly shown during the 
treatment with FCsPNP as compared to CsPNP and IHCl. It is 
due to the targeting efficacy of folic acid to the folate 
receptors. Antitumor Activity is seen when T/C values ≤ 0.4. 
The results show that FCsPNP is showing antitumor activity 
during the study period whereas CsPNP is successful in 
controlling the tumor growth up to some extent (T/C values 
is nearly equal to 0.5). Earlier studies on SN-38 oral delivery 
were limited to in vitro cytotoxicity studies 20,49,50. The in vivo 
studies of the present research shows antitumor efficacy 
after oral delivery of polymeric nanoparticles of SN-38. 
 
Table 1: In vitro evaluation parameters of CsPNP and FCsPNP (n=3, Data represents Mean±S.D, P<0.05) 
Formulation 
code 
Particle size 
(nm) 
Zeta potential 
(mV) 
Drug entrapment 
efficiency (%) 
Drug loading 
(%) 
PdI 
CsPNP 225.5± 3.75 27.6 ± 0.173 78.3± 0.44 13.5± 0.4 0.157 ± 0.0036 
FCsPNP 310 ± 2.5 15.6 ±1.8 78.7 ± 1.6 13.6 ± 0.6 0.571 ± 0.03 
 
Table 2: Percent survival of xenograft models at different time points for different groups 
Weeks Days Control FCsPNP CsPNP IHCl 
0.00 1 100 100 100 100 
0.71 5 100 100 100 100 
1.29 9 100 100 100 100 
1.71 12 100 100 100 100 
2.14 15 100 100 100 100 
2.57 18 100 100 100 100 
3.00 21 100 100 100 100 
3.57 25 100 100 100 67 
4.00 28 83 100 83 67 
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Table 3: Tumour volume in cm3 of different groups treated with nanoparticles at different time points during 30 days 
study (n=6, Data represents Mean±S.D, P<0.05) 
Week Days Control FCsPNP CsPNP IHCl 
  
Tumour volume 
0.00 1 0.05±0.01 0.05±0.01 0.04±0.01 0.04±0.01 
0.71 5 0.33±0.09 0.07±0.02 0.11±0.04 0.15±0.06 
1.29 9 1.37±0.61 0.30±0.12 0.81±0.24 1.12±0.32 
1.71 12 2.89±0.74 0.49±0.19 1.26±0.47 1.53±0.41 
2.14 15 3.60±0.71 0.93±0.46 1.93±0.84 2.49±0.38 
2.57 18 5.09±0.87 1.37±0.56 2.38±0.84 3.19±0.51 
3.00 21 6.07±1.00 1.75±0.72 3.18±0.75 3.95±0.56 
3.57 25 6.91±0.78 2.32±0.89 4.17±0.96 4.37±0.52 
4.00 28 7.77±1.55 2.53±0.77 4.38±0.75 4.66±0.41 
 
Table 4: Animal weight in grams at different days during treatment period of 30 days (n=6, Data represents Mean±S.D, 
P<0.05 ) 
Weeks Days Control FCsPNP CsPNP IHCl 
0.00 1 22.9±0.5 22±0.8 23.1±0.7 22.0±0.6 
0.71 5 23.1±0.4 21.0±0.9 22.8±0.3 19.7±0.7 
1.29 9 22.5±0.6 21.1±0. 23.1±0.2 19.5±0.2 
1.71 12 22.7±0.4 20.8±0.4 22.9±0.8 19.3±0.6 
2.14 15 22.6±0.1 19.1±0.6 22.2±1.0 19.0±0.5 
2.57 18 23.0±0.2 19.6±0.9 21.6±0.8 18.8±0.4 
3.00 21 23.2±0.5 19.4±1.0 21.4±0.9 18.7±0.3 
3.57 25 23.5±0.7 19.6±0.8 21.4±0.7 18.5±0.8 
4.14 29 24.2±0.3 20.5±0.3 21.9±0.2 18.6±0.4 
Table 5: Data of T/C values of different groups with respect to days 
 
 
 
 
 
 
 
Weeks Days FCsPNP CsPNP IHCl 
 1 1 1 1 
0.00 5 0.238572 0.510278754 0.692171 
0.71 9 0.273985 0.919423793 1.291801 
1.29 12 0.273015 0.907288638 1.095923 
1.71 15 0.317109 0.886828463 1.080931 
2.14 18 0.330839 0.758162939 1.006423 
2.57 21 0.3586 0.833361711 1.021854 
3.00 25 0.408758 0.942047971 1.047742 
3.57 28 0.385722 0.892929536 0.955581 
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Figure 1: Schematic diagram of conjugation of folic acid with CHI-PLGA Polyelectrolytic complex 
 
 
Figure 2: Cumulative % release of SN-38 A) from CsPNP in simulated gastric fluids B) from CsPNP and SN-38 in PBS (pH 
7.4) and C) from FCsPNP in PBS (pH 7.4) 
Prasad et al                                                                                                           Journal of Drug Delivery & Therapeutics. 2019; 9(4-s):322-331 
ISSN: 2250-1177                                                                                  [328]                                                                                 CODEN (USA): JDDTAO 
 
Figure 3: TEM images of A) Blank CsPNP B) SN-38 loaded CsPNP and C) FCsPNP 
 
 
  
 
Figure 4: SEM images of A) Blank CsPNP B) SN-38 loaded CsPNP and C) FCsPNP 
 
C 
A 
C 
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Figure 5:  Graphs of A) % survival of animals at different time points B) Tumor volume in cm3 of different groups 
treated with nanoparticles with respect to days C) Average animal weight in grams with respect to days taken at 
different days during 30 days study and D) T/C values from RTV data of different groups with respect to days (n=6, 
Data represents Mean±S.D) 
 
 
Figure 6: Photographs of Colon tumor xenograft mice of different groups on 1st day and last day of treatment 
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CONCLUSIONS 
Polymeric nanoparticles and targeted nanoparticles of SN-38 
were successfully prepared and evaluated for in vitro and in 
vivo characterization. In vitro drug release studies in 
simulated fluids showed sustained action of CsPNP and 
targeted action of FCsPNP. The relation between formulation 
additives and product performance was elucidated by drug 
release studies. The formulations were found to be less toxic 
and effective in treatment of colorectal cancer. Thus 
polymeric nanoparticles prepared by polyelectrolyte 
complexation method are a viable approach for oral 
chemotherapy.  
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